Cargando…
The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study
BACKGROUND: Minimal hepatic encephalopathy (MHE) is clinically undetectable and the diagnosis requires psychometric tests. However, a lack of clarity exists as to whether the tests are in fact able to detect changes in cognition. AIM: To examine if the continuous reaction time test (CRT) can detect...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636096/ https://www.ncbi.nlm.nih.gov/pubmed/29020023 http://dx.doi.org/10.1371/journal.pone.0185412 |
_version_ | 1783270383513763840 |
---|---|
author | Lauridsen, M. M. Mikkelsen, S. Svensson, T. Holm, J. Klüver, C. Gram, J. Vilstrup, H. Schaffalitzky de Muckadell, O. B. |
author_facet | Lauridsen, M. M. Mikkelsen, S. Svensson, T. Holm, J. Klüver, C. Gram, J. Vilstrup, H. Schaffalitzky de Muckadell, O. B. |
author_sort | Lauridsen, M. M. |
collection | PubMed |
description | BACKGROUND: Minimal hepatic encephalopathy (MHE) is clinically undetectable and the diagnosis requires psychometric tests. However, a lack of clarity exists as to whether the tests are in fact able to detect changes in cognition. AIM: To examine if the continuous reaction time test (CRT) can detect changes in cognition with anti-HE intervention in patients with cirrhosis and without clinically manifest hepatic encephalopathy (HE). METHODS: Firstly, we conducted a reproducibility analysis and secondly measured change in CRT induced by anti-HE treatment in a randomized controlled pilot study: We stratified 44 patients with liver cirrhosis and without clinically manifest HE according to a normal (n = 22) or abnormal (n = 22) CRT. Each stratum was then block randomized to receive multimodal anti-HE intervention (lactulose+branched-chain amino acids+rifaximin) or triple placebos for 3 months in a double-blinded fashion. The CRT is a simple PC-based test and the test result, the CRT index (normal threshold > 1.9), describes the patient’s stability of alertness during the 10–minute test. Our study outcome was the change in CRT index in each group at study exit. The portosystemic encephalopathy (PSE) test, a paper-and-pencil test battery (normal threshold above -5), was used as a comparator test according to international guidelines. RESULTS: The patients with an abnormal CRT index who were randomized to receive the active intervention normalized or improved their CRT index (mean change 0.92 ± 0.29, p = 0.01). Additionally, their PSE improved (change 3.85 ± 1.83, p = 0.03). There was no such effect in any of the other study groups. CONCLUSION: In this cohort of patients with liver cirrhosis and no manifest HE, the CRT identified a group in whom cognition improved with intensive anti-HE intervention. This finding infers that the CRT can detect a response to treatment and might help in selecting patients for treatment. |
format | Online Article Text |
id | pubmed-5636096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-56360962017-10-30 The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study Lauridsen, M. M. Mikkelsen, S. Svensson, T. Holm, J. Klüver, C. Gram, J. Vilstrup, H. Schaffalitzky de Muckadell, O. B. PLoS One Research Article BACKGROUND: Minimal hepatic encephalopathy (MHE) is clinically undetectable and the diagnosis requires psychometric tests. However, a lack of clarity exists as to whether the tests are in fact able to detect changes in cognition. AIM: To examine if the continuous reaction time test (CRT) can detect changes in cognition with anti-HE intervention in patients with cirrhosis and without clinically manifest hepatic encephalopathy (HE). METHODS: Firstly, we conducted a reproducibility analysis and secondly measured change in CRT induced by anti-HE treatment in a randomized controlled pilot study: We stratified 44 patients with liver cirrhosis and without clinically manifest HE according to a normal (n = 22) or abnormal (n = 22) CRT. Each stratum was then block randomized to receive multimodal anti-HE intervention (lactulose+branched-chain amino acids+rifaximin) or triple placebos for 3 months in a double-blinded fashion. The CRT is a simple PC-based test and the test result, the CRT index (normal threshold > 1.9), describes the patient’s stability of alertness during the 10–minute test. Our study outcome was the change in CRT index in each group at study exit. The portosystemic encephalopathy (PSE) test, a paper-and-pencil test battery (normal threshold above -5), was used as a comparator test according to international guidelines. RESULTS: The patients with an abnormal CRT index who were randomized to receive the active intervention normalized or improved their CRT index (mean change 0.92 ± 0.29, p = 0.01). Additionally, their PSE improved (change 3.85 ± 1.83, p = 0.03). There was no such effect in any of the other study groups. CONCLUSION: In this cohort of patients with liver cirrhosis and no manifest HE, the CRT identified a group in whom cognition improved with intensive anti-HE intervention. This finding infers that the CRT can detect a response to treatment and might help in selecting patients for treatment. Public Library of Science 2017-10-11 /pmc/articles/PMC5636096/ /pubmed/29020023 http://dx.doi.org/10.1371/journal.pone.0185412 Text en © 2017 Lauridsen et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Lauridsen, M. M. Mikkelsen, S. Svensson, T. Holm, J. Klüver, C. Gram, J. Vilstrup, H. Schaffalitzky de Muckadell, O. B. The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study |
title | The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study |
title_full | The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study |
title_fullStr | The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study |
title_full_unstemmed | The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study |
title_short | The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—A pilot study |
title_sort | continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—a pilot study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636096/ https://www.ncbi.nlm.nih.gov/pubmed/29020023 http://dx.doi.org/10.1371/journal.pone.0185412 |
work_keys_str_mv | AT lauridsenmm thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy AT mikkelsens thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy AT svenssont thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy AT holmj thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy AT kluverc thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy AT gramj thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy AT vilstruph thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy AT schaffalitzkydemuckadellob thecontinuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy AT lauridsenmm continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy AT mikkelsens continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy AT svenssont continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy AT holmj continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy AT kluverc continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy AT gramj continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy AT vilstruph continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy AT schaffalitzkydemuckadellob continuousreactiontimetestforminimalhepaticencephalopathyvalidatedbyarandomizedcontrolledmultimodalinterventionapilotstudy |